Treatment of Metastatic or Advanced Undifferentiated Pleomorphic Sarcoma
Clinical scenario
This protocol covers undifferentiated pleomorphic sarcoma (UPS) presenting in the metastatic or advanced setting, where systemic therapy is the primary treatment modality.
Setting
In the metastatic setting, single-agent or combination chemotherapy is generally the first-line approach for UPS, with agent selection guided by available evidence from soft-tissue sarcoma studies and individual patient factors.
Treatment approach
For advanced or metastatic UPS, several systemic agents have demonstrated activity — including at least one chemotherapy-based combination and a targeted therapy option. The complete protocol specifies the preferred agents, selection criteria, and clinical decision points.
DOI: 10.1200/JCO.2017.
In the metastatic setting, doxorubicin as a single agent or in combination with ifosfamide or olaratumab is likely to be the first choice of chemotherapy, which assumes that the findings with these treatments in other STSs also are applicable to UPS.
Other drugs such as trabectedin, gemcitabine and docetaxel, and pazopanib also have shown activity in the advanced setting.
View source ↗